IMPORTANT
SAFETY
INFORMATION FULL
PRESCRIBING
INFORMATION PATIENT
INFORMATION MEDICAL
INFORMATION PATIENT
SITE

Coverage your patients can count on

Xiidra is covered for most patients in the US¹

Not an actual patient.

Not an actual patient.

Coverage your patients can count on

Xiidra is covered for most patients in the US¹

IN THIS SECTION

Xiidra has ~90% OVERALL COVERAGE for Medicare Part D and commercial patients nationwide¹*

COMMERCIAL

Xiidra coverage exceeds Restasis^® in most major plans^1†

PAY $0

With Xiidra, eligible commercial patients pay $0 for their first Rx^2‡

When using the Xiidra Co-pay Card, 90% of eligible commercial patients paid $0^3‡§

MEDICARE PART D

Xiidra offers equal coverage to Restasis^® in most major plans⁴

Don’t let coverage concerns drive your prescribing decisions

Choose Xiidra, which is widely accepted by insurance plans for most patients.¹

For patients experiencing financial hardship, and have limited or no prescription coverage, contact 1-877-4XiiDRA (1-877-494-4372) or visit www.patientassistance.bausch.com.

Patients who are eligible may receive their medication for free.

For more on helping patients start and stay on Xiidra, including questions around cost and affordability such as Xiidra’s $0 Co-Pay Program for commercially eligible patients or the Insider Support Program, please call the Xiidra Access Program at 1-877-4XiiDRA (1-877-494-4372).

Xiidra Prior Authorization Checklist

Ensure seamless access assistance for appropriate patients with this easy-to-use Prior Authorization Checklist

DOWNLOAD

Xiidra patient
resources

Help your patients learn more about Xiidra and the relief it can offer for their dry eye symptoms.

Go to the patient site

*Based on data from December 2023. Up to 66% of Medicare Part D and 94% of commercial patients may be covered.

^†Plan limitations may apply.

^‡Terms and conditions apply. For the first 30-day, 60-day, or 90-day prescription. Subject to benefit limitations. Visit Xiidra.com for complete terms and conditions.

^§From data on file: Average payments between January 1 and December 6 of 2023, ConnectiveRx data.

Indication

Xiidra^® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra^® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.

Coverage your patients can count on

Coverage your patients can count on

Xiidra has ~90% OVERALL COVERAGE for Medicare Part D and commercial patients nationwide1*

COMMERCIAL

PAY $0

MEDICARE PART D

Xiidra Prior Authorization Checklist

Xiidra patient resources

Xiidra has ~90% OVERALL COVERAGE for Medicare Part D and commercial patients nationwide¹*

Xiidra patient
resources